The launch of Sandoz's Tyruko biosimilar of Tysabri (natalizumab) comes two years after the product was approved by the FDA, ...

As the Jefferies Healthcare conference gets underway this week in London, pharmaphorum had the chance to connect with the CEO ...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical ...

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy US biotech Halda Therapeutics and ...

BMS and J&J's Librexia AF study is also comparing milvexian to Eliquis to see if it can prevent stroke and other clotting ...

AbbVie has turned to award-winning, Oscar-nominated director Dominic Gill to help it highlight the lives of people living ...

The announcement takes the total raised by Sofinnova Partners in the last year to €1.5 billion, and comes shortly after Anglo ...

A 2024 survey by the American Medical Association showed that physician usage of AI jumped 78% in a single year, which tells ...

The FDA is also requiring Sarepta to conduct an additional post-marketing observational study to further assess the risk of ...

Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead as generic competition and litigation liabilities bed in. Pharma ...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas, about ...